Zydus Lifesciences launches Rexigo, testosterone suppression oral therapy for advanced prostate cancer, ET HealthWorld


Ahmedabad: Zydus Lifesciences Ltd announced that it has launched Relugolix under the brand name, Rexigo. This is the first and only oral once-a-day therapy for testosterone suppression in patients with advanced prostate cancer in India. With this launch, the company brings access to a critical therapy and also makes it affordable for Rs 6995 per month which is 50 per cent less than the currently available injectable options. The drug will be manufactured at the group’s manufacturing premises.

One of the key strategies of prostate cancer management is ‘androgen deprivation therapy’ (ADT) to suppress testosterone levels. It can be achieved by surgery or by using drugs. The duration of ADT depends on the disease status. The drugs currently used for treatment are all injectables with different routes of administration (in muscle or under the skin) and can be done only under the supervision of a caregiver. Rexigo alleviates this need. With this, the treatment for prostate cancer in India can now be made completely oral.

It shows rapid testosterone suppression which can be sustained throughout the treatment period. It also has a better safety profile for heart-related adverse events. Testosterone recovery is faster once Relugolix is stopped, so it is beneficial to patients needing suppression only for a fixed duration as a part of their treatment plan.

  • Published On Jan 30, 2024 at 08:35 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *